Immune control by amino acid catabolism during tumorigenesis and&#160;therapy (Q91272360)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30696923 AND SRC:MED&resulttype=core&format=json

21 April 2020

title

Immune control by amino acid catabolism during tumorigenesis and therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30696923 AND SRC:MED&resulttype=core&format=json

21 April 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30696923 AND SRC:MED&resulttype=core&format=json

21 April 2020

author name string

Henrique Lemos

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30696923 AND SRC:MED&resulttype=core&format=json

21 April 2020

George C Prendergast

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30696923 AND SRC:MED&resulttype=core&format=json

21 April 2020

Andrew L Mellor

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30696923 AND SRC:MED&resulttype=core&format=json

21 April 2020

publication date

1 March 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30696923 AND SRC:MED&resulttype=core&format=json

21 April 2020

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30696923 AND SRC:MED&resulttype=core&format=json

21 April 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30696923 AND SRC:MED&resulttype=core&format=json

21 April 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30696923 AND SRC:MED&resulttype=core&format=json

21 April 2020

page(s)

162-175

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30696923 AND SRC:MED&resulttype=core&format=json

Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression

21 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Polyamine metabolism and cancer: treatments, challenges and opportunities

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

A new cancer immunotherapy suffers a setback

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

A high-affinity, tryptophan-selective amino acid transport system in human macrophages

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Translational control in the endoplasmic reticulum stress response

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Signaling through alternative Integrated Stress Response pathways compensates for GCN2 loss in a mouse model of soft tissue sarcoma

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

mTOR signalling and cellular metabolism are mutual determinants in cancer

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Genetic Disruption of the Multifunctional CD98/LAT1 Complex Demonstrates the Key Role of Essential Amino Acid Transport in the Control of mTORC1 and Tumor Growth

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

ASC amino acid transporter 2, defined by enzyme-mediated activation of radical sources, enhances malignancy of GD2-positive small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

mTORC1 Activator SLC38A9 Is Required to Efflux Essential Amino Acids from Lysosomes and Use Protein as a Nutrient.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

IDO is a nodal pathogenic driver of lung cancer and metastasis development

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

CpG oligodeoxynucleotide-based therapy of lymphoid malignancies.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

The interferon response to intracellular DNA: why so many receptors?

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

IDO2 in Immunomodulation and Autoimmune Disease

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Tryptophan availability for kynurenine pathway metabolism across the life span: Control mechanisms and focus on aging, exercise, diet and nutritional supplements

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

The Many Neuroprogressive Actions of Tryptophan Catabolites (TRYCATs) that may be Associated with the Pathophysiology of Neuro-Immune Disorders.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Indoleamine 2,3-dioxygenase 1, Increased in Human Gastric Pre-Neoplasia, Promotes Inflammation and Metaplasia in Mice and is Associated with Type II Hypersensitivity/Autoimmunity

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Discovery of IDO1 Inhibitors: From Bench to Bedside

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Upregulated expression of indoleamine 2, 3-dioxygenase in primary breast cancer correlates with increase of infiltrated regulatory T cells in situ and lymph node metastasis

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

High expression of indoleamine 2,3-dioxygenase gene in prostate cancer

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

A sense of tumour for the immune system

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

L-arginine availability regulates T-lymphocyte cell-cycle progression

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Reprogrammed foxp3( ) regulatory T cells provide essential help to support cross-presentation and CD8( ) T cell priming in naive mice

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

An inherently bifunctional subset of Foxp3 T helper cells is controlled by the transcription factor eos.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Myeloid-derived suppressor cells in cancer patients: a clinical perspective.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Regulation of immune responses by L-arginine metabolism

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Cutting edge: CpG oligonucleotides induce splenic CD19 dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Marginal zone CD169 macrophages coordinate apoptotic cell-driven cellular recruitment and tolerance

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Engineering DNA nanoparticles as immunomodulatory reagents that activate regulatory T cells

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Ligation of B7-1/B7-2 by human CD4 T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Physiologic Control of IDO Competence in Splenic Dendritic Cells

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Extrinsic Phagocyte-Dependent STING Signaling Dictates the Immunogenicity of Dying Cells.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Apoptotic cell-induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Protective tolerance to fungi: the role of IL-10 and tryptophan catabolism

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

The IDO inhibitor 1-methyl tryptophan activates the aryl hydrocarbon receptor response in mesenchymal stromal cells.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Is chronic AhR activation by rapidly metabolized ligands safe for the treatment of immune-mediated diseases?

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

The metabolite BH4 controls T cell proliferation in autoimmunity and cancer

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

The endogenous tryptophan metabolite and NAD precursor quinolinic acid confers resistance of gliomas to oxidative stress

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Medical anticancer treatment of lung cancer associated with comorbidities: a review

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Cytokines and depression: the need for a new paradigm

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

5-hydroxytryptamine receptor (5-HT1DR) promotes colorectal cancer metastasis by regulating Axin1/β-catenin/MMP-7 signaling pathway

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Serotonergic system antagonists target breast tumor initiating cells and synergize with chemotherapy to shrink human breast tumor xenografts

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

A patent review of IDO1 inhibitors for cancer.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Host type I IFN signals are required for antitumor CD8 T cell responses through CD8{alpha} dendritic cells

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Activation of the STING adaptor attenuates experimental autoimmune encephalitis.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Liver injury from cancer immunotherapy using monoclonal immune checkpoint inhibitors

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

IFN-α in the treatment of melanoma

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Bi

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

ATIM-29. A PHASE 1 STUDY OF PF-06840003, AN ORAL INDOLE 2,3-DIOXYGENASE 1 (IDO1) INHIBITOR IN PATIENTS WITH MALIGNANT GLIOMAS

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8( ) T cells

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8( ) T cells directly within the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

PDCT-06. RADIO-IMMUNOTHERAPY USING THE IDO-INHIBITOR INDOXIMOD IN COMBINATION WITH RE-IRRADIATION FOR CHILDREN WITH PROGRESSIVE BRAIN TUMORS IN THE PHASE 1 SETTING: AN UPDATED REPORT OF SAFETY AND TOLERABILITY (NCT02502708)

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Abscopal effect in a patient with melanoma

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

A systemic complete response of metastatic melanoma to local radiation and immunotherapy.

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Immunologic correlates of the abscopal effect in a patient with melanoma

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients

1 reference

https://api.crossref.org/works/10.1038/S41568-019-0106-Z

7 January 2021

10.1038/S41568-019-0106-Z

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30696923 AND SRC:MED&resulttype=core&format=json

21 April 2020

1 reference